Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.82 |
| ▸ | JAK2 | O60674 | 3/20 | 0.79 |
| ▸ | JAK1 | P23458 | 3/20 | 0.76 |
| ▸ | STAT3 | P40763 | 1/20 | 0.76 |
| ▸ | STAT1 | P42224 | 1/20 | 0.76 |
| ▸ | JAK3 | P52333 | 1/20 | 0.76 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30968156 | 1.00 | TYK2 (0.82) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL26041930 | 0.91 | TYK2 (0.82) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL22647341 | 0.90 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL31369028 | 0.90 | TYK2 (0.87) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL30065968 | 0.90 | TYK2 (0.81) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL23096153 | 0.90 | TYK2 (0.87) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL22647338 | 0.90 | TYK2 (0.87) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL22263494 | 0.90 | TYK2 (0.87) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL22313877 | 0.90 | TYK2 (0.81) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL32691810 | 0.90 | TYK2 (0.87) | TYK2JAK2JAK1STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113227071-B | Amide-substituted heterocyclic compounds for the treatment of disorders associated with modulation of IL-12, IL-23 and/or IFN-alpha | 百时美施贵宝公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230020273-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3873892-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | Bristol-Myers Squibb Company (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113227071-A | Amide-substituted heterocyclic compounds for the treatment of disorders associated with the modulation of IL-12, IL-23 and/or IFN-alpha | 百时美施贵宝公司 | 2021-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020273-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | TYK2, IFNG, JAK3 | TYK2 1/4885JAK2 7/4885JAK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.